EGFR and non-small cell lung carcinoma: In view of these researches, exploring the clinical effect of SFI plus EGFR-TKIs regimen in patients with EGFR mutation and providing relevant data evidence for its use in the comprehensive treatment of NSCLC patients present an imperative task.